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The incidence of esophageal squamous cell carcinoma 
(ESCC) is very high among the Turkmen population of 
Iran. Family studies suggest a genetic component to the 
disease. Turkmen are ethnically homogenous and are well 
suited for genetic studies. A previous study from China 
suggested that BRCA2 might play a role in the etiology of 
ESCC. We screened for mutations in the coding region of 
the BRCA2 gene in the germline DNA of 197 Turkmen 
patients with ESCC. A nonsense variant, K3326X, was 
identiﬁed in 9 of 197 cases (4.6%) vs 2 of 254 controls 
(0.8%) (OR ¼ 6.0, 95% CI ¼ 1.3–28; P ¼ 0.01). This 
mutation leads to the loss of the C-terminal domain of the 
BRCA2 protein, a part of the region of interaction with 
the FANCD2 protein. We observed nine other BRCA2 
variants in single cases only, including two deletions, and 
seven missense mutations. Six of these were judged to be 
pathogenic. In total, a suspicious deleterious BRCA2 
variant was identiﬁed in 15 of 197 ESCC cases (7.6%). 
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doi:10.1038/sj.onc.1210739 
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Introduction 
The southeastern part of Caspian littoral of Iran, which 
is inhabited mainly by Turkmen, is the western-most 
extremity of a region with a high incidence of 
esophageal cancer that extends eastward to the north 
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of China (Schottenfeld, 1984). The incidence of esopha­
geal cancer in the Turkmen population is among the 
highest in the world, with an annual incidence rate of 
more than 100 per 100 000 (Mahboubi et al., 1973; Saidi 
et al., 2000). More than 90% of all esophageal cancers in 
Turkmen are squamous cell carcinomas (Islami et al., 
2004). The Turkmen are genetically homogenous and 
are well suited for genetic studies of esophageal 
squamous cell carcinoma (ESCC). 
In addition to several proposed environmental fac­
tors, a number of studies have reported clustering of the 
disease in families (Pour and Ghadirian, 1974; Ghadir­
ian, 1985). Recently, we reported a strong familial 
component to ESCC among Turkmen (Akbari et al., 
2006). Esophageal cancer was signiﬁcantly more com­
mon in the ﬁrst-degree relatives of the cases than the 
relatives of unaffected controls (62% vs 31%, 
P ¼ 2 x 10-8). We estimated the cumulative risk of 
esophageal cancer in the ﬁrst-degree relatives of the 
cases to be 34% by the age of 75, compared to 14% for 
the relatives of the controls (hazard ratio ¼ 2.3; 
P ¼ 3 x 10-8). This suggests that the genetic factors 
may contribute to the high incidence rate of esophageal 
cancer among Turkmen. 
In a study of Chinese patients with ESCC, a genome-
wide scan using polymorphic micro-satellite markers 
showed a high frequency of loss of heterozygosity on a 
region of chromosome 13q (Hu et al., 2000). Two of the 
informative markers in this region (D13S260 and 
D13S267) are adjacent to BRCA2 (Li et al., 2001). 
Subsequent studies among high-risk Chinese popula­
tions (Hu et al., 2002, 2003, 2004) suggested that 
BRCA2 mutations may contribute to the development 
of ESCC, especially in those with a family history of 
upper GI cancers. 
BRCA2 was identiﬁed as a breast cancer susceptibility 
gene in 1995 (Wooster et al., 1995). Germline mutations 
of BRCA2 also contribute to the development of 
ovarian (Narod, 2002), prostate (Simard et al., 2003) 
and pancreatic cancers (Lowenfels and Maisonneuve, 
2005). Moreover, biallelic BRCA2 mutations cause 
Fanconi anemia (FA) (Howlett et al., 2002; Ofﬁt et al., 
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2003). BRCA2 is mainly involved in homologous 
recombination repair through control of RAD51 
recombinase (Pellegrini et al., 2002) and it interacts 
with many other proteins involved in various cellular 
functions, including cell cycle regulation (Marmorstein 
et al., 2001), transcription regulation (Milner et al., 
1997), cytokinesis (Daniels et al., 2004) and control of 
cell proliferation (Tian et al., 2005). 
In the current study, we scanned the germline DNA of 
197 Turkmen ESCC cases for BRCA2 mutations. We 
then screened 254 Turkmen controls for the mutations 
detected in cases to evaluate whether mutations in this 
gene are associated with elevated ESCC risk in the 
Turkmen population of Iran. 
Results 
We studied 197 Turkmen cases of ESSC, including 114 
men and 83 women. The mean age at diagnosis was 
64.0711 years (range 30–86). A family history of 
esophageal cancer was reported for 144 (73.1%) of the 
cases. The control group consisted of 254 Turkmen 
individuals (113 men and 141 women) from hospital 
patients who had diagnoses other than cancer. The 
mean age of controls was 59712 years. 
We identiﬁed the K3326X nonsense variant in nine 
cases (4.6%) and two controls (0.8%) (OR ¼ 6.0, 95% 
CI ¼ 1.3–28; P ¼ 0.01). None were related to each other. 
Eight cases and one of the controls had a family history 
of esophageal cancer (Table 3). The variant was more 
frequent among familial cases (8/144; 5.5%) than 
controls (2/254; 0.8%) (OR ¼ 7.4, 95% CI ¼ 1.6–36; 
P ¼ 0.005). This mutation leads to premature truncation 
of the BRCA2 protein and the loss of half of the amino 
acids coded by exon 27 (Mazoyer et al., 1996). The mean 
age at diagnosis of ESCC for the nine patients with the 
K3326 variant was 62.3 years, similar to the age of 
diagnosis in cases without this variant (64.1 years). The 
pathologic tumor grades of the cases with the K3326X 
variant were not different from other cases. The 
K3326X nonsense variant was completely in linkage 
disequilibrium (LD) with an intronic variant IVS24­
16T>C in cases and controls (r2 ¼ 1.0). 
In addition to the K3326X variant, we detected two 
deletions and seven unique missense mutations. The two 
deletions (501delCCAATCTCCTGTA and 3734delA) 
were found in patients who had no family history of 
esophageal or other cancer (Table 1). Seven patients had 
a unique missense variant (Y42C, C315S, L1019V, 
I2490T, T2542M, K2729N and Q3227E). Five of these 
patients had a family history of esophageal or other 
cancer. Four of the missense variants (Y42C, C315S, 
I2490T and K2729N) were judged to be deleterious and 
two others (L1019V and T2542M) are likely to be 
benign, based on available evidence, including the 
impact of the mutation on the BRCA2 protein structure, 
and the potential interaction with other proteins (see 
discussion). There is not enough information available 
to assess the effect of the Q3227E variant on the BRCA2 
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protein. We evaluated the 254 controls for the presence 
of these seven missense variants and the 3734delA 
deletion, but none was detected. 
The I3412V variant was identiﬁed frequently among 
both cases (12/197; 6.1%) and controls (20/245; 8.2%) 
(P ¼ 0.8). Other silent variants and intronic polymorph­
isms are listed in Table 2. 
In summary, we identiﬁed a deleterious mutation in 
15 of 197 ESCC cases (7.6%). The frequency of BRCA2 
deleterious mutations among ESCC cases (7.6%) was 
signiﬁcantly higher than controls (2/254; 0.8%) 
(OR ¼ 10.4, 95% CI ¼ 2.3–46; P ¼ 0.0002). There was 
no synergistic effect between BRCA2 mutations and any 
of the conventional environmental risk factors, such as 
smoking and alcohol drinking (data not shown). 
Discussion 
We screened the entire coding region of BRCA2 in the 
germline DNA of 197 Turkmen patients with ESCC. 
Two deletions were identiﬁed which are predicted to be 
deleterious. These include a deletion of 13 nucleotides at 
position 501–513, which results in frameshift translation 
and a premature ocher stop codon (UAA) at codon 91. 
The second deletion found was a single nucleotide 
deletion at position 3734 in BRCA2 that leads to a 
premature amber stop codon (UAG) at codon 1176. 
This truncated BRCA2 protein is missing domains that 
are crucial for DNA repair function. It is interesting 
that, although these are typical of deleterious BRCA2 
mutations, neither of these patients had a family history 
of breast or ovarian cancer (Table 1). 
We found the nonsense variant K3326X in nine of our 
ESCC cases, eight of whom had a family history of 
esophageal cancer. The association between this variant 
and ESCC risk was statistically signiﬁcant (OR ¼ 6.0, 
95% CI ¼ 1.3–28; P ¼ 0.01). The pathogenicity of this 
variant regarding breast cancer risk has been questioned 
(Mazoyer et al., 1996); however, we believe that our data 
support that it is predisposing for ESCC. Martin et al. 
(2005) reported the K3326X variant to be more 
prevalent among patients with familial pancreatic cancer 
than those in controls (OR ¼ 4.8, 95% CI ¼ 1.3–19; 
Po0.01). The allele frequency of the K3326X variant 
has been reported to be 0% in Asian, 0% in Sub-
Saharan African and 1.7% European populations 
(International HapMap Consortium, 2005). In our 
study, the frequency among ESCC patients from a 
Turkmen population (which is believed to have a genetic 
background more similar to East Asians than those of 
HapMap populations) was 4.6% and among controls 
was 0.8%. None of our cases and controls who were 
carriers of this variant had any other deleterious 
mutation in BRCA2; however, the IVS24-16T>C and 
Table 2 Germline BRCA2 polymorphisms detected in 197 Turkmen ESCC patients 
No Base change Amino-acid change Number of heterozygote patients (%) Number of homozygote patients (%) 
1 50UTRG203A NA 31 (15.7) 8 (4.1) 
2 IVS 4+67 A>C NA 30 (15.2) 1 (0.5) 
3 A3624G L1132L 1 (0.5) 0 (0.0) 
4 T4035C V1269V 1 (0.5) 0 (0.0) 
5 IVS 12+34 C>T NA 1 (0.5) 0 (0.0) 
6 A7470G S2414S 22 (11.2) 10 (5.1) 
7 IVS17-14 T>C NA 30 (15.2) 16 (8.1) 
8 IVS 19+82 G>A NA 4 (2.0) 0 (0.0) 
9 C9132A T2968T 11 (5.6) 0 (0.0) 
10 IVS24-16 T>C NA 9 (4.6) 0 (0.0) 
11 C10251T D3341D 1 (0.5) 0 (0.0) 
12 G10338A R3370R 1 (0.5) 0 (0.0) 
13 A10462G I3412V 12 (6.1) 0 (0.0) 
Abbreviations: ESCC, esophageal squamous cell carcinoma; NA, not applicable. 
Table 3 Demographic information of cases and controls with the K3326X nonsense variant in BRCA2 
ID Group Gender Age at diagnosis Family history of esophageal cancer 
P28218 Control Female 76 Maternal ﬁrst cousin 
P28309 Case Female 70 Mother, paternal uncle, maternal aunt, maternal ﬁrst cousin 
P28326 Case Male 42 Maternal uncle 
P28350 Case Male 37 Father, paternal ﬁrst cousin 
P28482 Case Male 67 Paternal uncle 
P28488 Case Female 79 Brother 
P28534 Control Male 68 No 
P28547 Case Female 53 Father, brother, paternal uncle 
P30812 Case Female 73 No 
P30850 Case Female 78 Paternal aunt, maternal ﬁrst cousin 
P30854 Case Male 62 Mother, sister 
Oncogene 
4 
BRCA2 mutations in esophageal squamous cell carcinoma 
MR Akbari et al 
K3326X variants which are 3816 bp away from each 
other were in complete LD, suggesting that the carriers 
of K3326X in the Turkmen population share a common 
ancestor. 
The BRCA2 variant K3326X results from mutation 
of adenosine to thymine at position 10 204 of exon 27 in 
the BRCA2 mRNA sequence, which leads to the ocher 
stop codon (UAA) and the truncation of 93 amino acids 
from the C terminus of the protein. Studies of mouse 
models suggest that the C terminus of BRCA2 is 
important in interacting with RAD51 (Mizuta et al., 
1997). Mouse cells with a BRCA2 exon 27 deletion 
showed hypersensitivity to ionizing radiation (Morimat­
su et al., 1998) and reduced life span (Donoho et al., 
2003). Mice with a homozygous deletion of exon 27 had 
increased susceptibility for various types of solid 
tumors, but not mammary tumors (McAllister et al., 
2002). This is consistent with the hypothesis that in 
humans, K3326X predisposes to malignant tumors of 
the pancreas and esophagus, but not to breast cancer. 
Howlett et al. (2002) reported biallelic inactivation of 
BRCA2 in a FA cell line which contained the K3326X 
variant as well as the frameshift mutation 3033de­
lAAAC in exon 11. FA is an autosomal recessive 
disorder characterized by cancer susceptibility and 
cellular hypersensitivity to DNA cross-linking agents 
(Joenje and Patel, 2001). BRCA2/FANCD1 is actually a 
member of a group of at least 13 different proteins 
which constitute the FA pathway (Taniguchi and 
D’Andrea, 2006; Reid et al., 2007). Eight of these 
proteins (FANCA, B, C, E, F, G, L and M) form a 
nuclear complex, known as the FA core complex, which 
is required for monoubiquitination of the FANCD2 
protein in response to DNA damage (Taniguchi and 
D’Andrea, 2006). Interaction of monoubiquitinated 
FANCD2 and BRCA2 in the C terminus of BRCA2 is 
essential for activation of RAD51 and for loading onto 
the damaged DNA (Wang et al., 2004; Atanassov et al., 
2005). Cells that express truncated BRCA2 protein, 
which lacks the C-terminal exon 27 coding region, do 
not show co-localization of FANCD2, BRCA2 and 
RAD51 on chromatin and are hypersensitive to cross-
linking agents like mitomycin C (Wang et al., 2004; 
Atanassov et al., 2005). Loss of the interaction between 
monoubiquitinated FANCD2 and BRCA2 on chroma­
tin and failure to load BRCA2 onto damaged chromatin 
is characteristic of all subtypes of FA cells (Wang et al., 
2004). FANCD2 knockout mice showed susceptibility 
to epithelial cancers (Houghtaling et al., 2003) which is 
comparable to that reported in mice with truncated 
BRCA2 lacking the exon 27 coding region (McAllister 
et al., 2002). This suggests that the functions of 
FANCD2 and the C terminus of BRCA2 are closely 
related (Houghtaling et al., 2003). 
According to available evidence, four of the missense 
variants observed here (Y42C, C315S, I2490T and 
K2729N) seem to be pathogenic and two (L1019V and 
T2542M) seem to be benign. There is insufﬁcient 
evidence to judge the effect of the Q3227E variant. 
The Y42C variant is located very close to the binding 
site of PALB2/FANCN (residues 10–40) in the BRCA2 
protein (Xia et al., 2006). By binding to BRCA2, PALB2 
promotes the stability of BRCA2 intranuclear localiza­
tion that is essential for its homologous recombination 
repair function (Xia et al., 2006). Moreover, the BRCA2 
transcription activation core sequence (Milner et al., 
1997) which is also the binding site for EMSY protein 
(Hughes-Davies et al., 2003) overlaps with the location 
of this variant. Because the side chains of tyrosine and 
cysteine are completely different, this variant might 
affect the structure and binding of BRCA2 with other 
proteins. Furthermore, tyrosine at codon 42 of BRCA2 
is highly conserved in vertebrate species. 
The missense variant C315S, which was identiﬁed in 
only one ESCC patient in our study, was reported in a 
total of 4 out of 246 patients from all three studies that 
scanned the BRCA2 gene in Chinese ESCC patients (Hu 
et al., 2002, 2003, 2004). Variant C315S is located in the 
region implicated in BRCA2-P/CAF complex formation 
(residues 290–453) which shows histone acetyltransfer­
ase activity (Fuks et al., 1998) that maybe responsible 
for the transcription regulatory function of BRCA2. 
Two additional missense variants (I2490T and K2729) 
result in amino acid changes in the same domain of the 
BRCA2 protein and may have a similar effect on the 
protein function. Structural crystallography of BRCA2 
and DSS1 shows that the isoleucine at codon 2490 and 
the lysine at codon 2729 of BRCA2 are involved in a-
helix and b-sheet structures of oligosaccharide-binding 
(OB) fold 1 (Yang et al., 2002). OB1 is also a site of 
interaction with FANCG protein—a proposed regulator 
for unloading of RAD51 from BRCA2 to the damaged 
DNA (Hussain et al., 2003). Both of these amino acids 
are also located in the binding domain of BRCA2 to 
MAGE-D1 protein (residues 2393–2952) a synergistic 
suppressor of cell proliferation (Tian et al., 2005). Both 
variants have been reported in FA patients with biallelic 
BRCA2 mutations, in combination with 5301insA and 
S2835X, respectively, (Howlett et al., 2002; Ofﬁt et al., 
2003). 
Out of the 38 previously identiﬁed missense variants 
in the BRC motifs region in exon 11, we only identiﬁed 
the I1019V variant in a single patient from a total of 451 
cases and controls. This exempliﬁes the importance of 
the eight BRC motifs, which are highly conserved in the 
genome and nucleotide changes in this area are rare. The 
BRC motifs are binding site of BRCA2 to RAD51 
(Pellegrini et al., 2002). Although isoleucine found at 
codon 1019 in the ﬁrst BRC motif, a valine is found in 
this position in ﬁve of the other seven motifs (Bork et al., 
1996). Because these two amino acids are structurally 
similar and both are hydrophobic, their substitution at 
this position seems to be benign. Structural crystal­
lography of BRCA2 in the region of the T2542M 
variant shows that threonine at codon 2542 does not 
have a special role in the secondary structure of BRCA2 
(Yang et al., 2002). Furthermore, threonine at this 
codon is not conserved in different species and even 
methionine is located at this position in the homologous 
BRCA2 protein in rat. 
In total, we identiﬁed deleterious BRCA2 mutations 
in 15 ESCC patients. Three mutations (I2490T, K2729N 
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and K3326X), which were seen in 11 patients, are 
located in domains which bind BRCA2 to other proteins 
in the FA pathway. Moreover, these three speciﬁc 
mutations have been seen in FA patients with biallelic 
BRCA2 mutations. Patients with FA are at increased 
risk of esophageal cancer. A review of 1301 FA patients 
showed the occurrence of 80 solid tumors among 68 
patients, nine of which were esophageal cancer and 26 
were classiﬁed head, neck or upper esophageal cancer 
(Alter et al., 2005). Rosenberg et al. (2003) studied 145 
FA patients and found 2 esophageal cancers and 6 head 
and neck carcinoma out of 18 solid tumors present in 
this group. The observed to expected incidence ratio was 
2362 (95% CI ¼ 265–8530) for esophageal cancer. 
Therefore, it is tempting to speculate that the BRCA2 
mutations, speciﬁcally those we identiﬁed in our cases 
(I2490T, K2729N and K3326X), increase the risk for 
development of ESCC by a mechanism related to FA 
pathway interruption. This may be a different mechan­
ism from that predisposes carriers of other BRCA2 
mutations to breast or ovarian cancer. Esophageal 
epithelial cells are exposed to exogenous carcinogens, 
some of which produce inter-strand DNA links which 
cannot be repaired in cells with defective HRR. Some 
other carcinogens cause double-strand DNA breaks 
repaired by error-prone non-homologous end joining 
pathway in absence of intact HRR. Inappropriate repair 
of damaged DNA results in loss of genome integrity and 
chromosomal instability that eventually leads to cancer 
development in esophageal epithelial tissue. Defective 
HRR in esophageal epithelial cells can result from the 
mutation of the wild-type copy of BRCA2 in cells which 
already have a germline BRCA2 mutation, thus leaving 
no copy of BRCA2 protein capable of binding to 
FANCD2 and FNACG proteins. Interruption of 
BRCA2 interaction with these FA pathway genes results 
in disruption of the FA pathway and consequently 
causes ineffective HRR. 
If correct, this model could have implications for the 
treatment of ESCC. If HRR is defective in ESCC cells of 
patients with BRCA2 mutations, we expect that ESCC 
tumors in these patients might be more sensitive to 
chemotherapeutic agents like cis-platin (which makes 
inter-strand DNA links which require HRR for their 
repair) than that of radiation which produces double-
strand breaks repaired by non-homologous end joining 
pathway (Houghtaling et al., 2005). We hope by 
determining the role of other FA genes in the develop­
ment of ESCC in future studies we can provide more 
evidence for this model. 
Materials and methods 
Study subjects 
This study is a part of an ongoing case–control study of UGI 
cancers (Islami et al., 2004) in the city of Gonbad, the second 
largest city of Golestan province, in northeastern Iran. The 
Digestive Disease Research Center (DDRC), Tehran Uni­
versity of Medical Sciences is running this project in 
collaboration with the National Cancer Institute and the 
International Agency for Research on Cancer. In total, 197 
Turkmen with ESCC and available blood samples were 
enrolled in this study. The diagnosis of ESCC was conﬁrmed 
for all cases by upper gastrointestinal endoscopy and 
pathologic evaluation of tumor biopsies. Cases and controls 
were collected between 1 August 2001 and 15 December 2005. 
The control group consisted of 254 Turkmen patients from the 
central city hospital (Khatam hospital) who had diagnoses 
other than cancer. The study protocol was approved by the 
ethics committee of the DDRC of Tehran University of 
Medical Sciences. 
Scanning of BRCA2 nucleotide changes 
A variety of methods were employed to detect the presence of 
BRCA2 nucleotide changes. Exons 10 and 11 of BRCA2 were 
scanned by the protein-truncation test (PTT). Primer se­
quences used to amplify overlapping fragments were obtained 
from the Breast Cancer Information Core (BIC) (http:// 
research.nhgri.nih.gov/projects/bic). PTT was performed by 
the TNT rabbit reticulocyte lysate system (Promega, Madison, 
WI, USA), with [35S]-methionine (New England Nuclear) for 
protein detection. All mutant bands detected by PTT were 
conﬁrmed by direct sequencing. 
Because most deleterious mutations in exons 10 and 11 of 
BRCA2 are truncating mutations, PTT is a standard method 
for mutation detection; however, structural crystallography of 
BRC motifs in exon 11 suggested that some missense variants 
in these regions could be deleterious (Pellegrini et al., 2002). As 
of 31 August 2006, 38 missense variants have been reported in 
the BIC database in the BRC motifs in exon 11, including the 
C315S variant (T1171A) in exon 10 which has been reported 
previously in a few families with ESCC (Hu et al., 2002, 2003, 
2004) were genotyped in all cases and controls using iPLEX 
chemistry on a MALDI-TOF MassARRAY system (Seque­
nom Inc., San Diego, CA, USA). The mutations detected in 
cases were also genotyped in controls by MassARRAY. All of 
the procedures were performed according to the manufac­
turer’s standard protocol. The average genotype call rate for 
this study was 98.4%. 
The remaining exons of BRCA2, exons 2–9 and 12–27, were 
scanned for ﬁnding mutations by the Denaturing High-
Performance Liquid Chromatography (DHPLC) method 
(Varian’s Helix system). Primer sequences used to amplify 
each amplicon were obtained from the BIC. To enhance 
heteroduplex formation, the PCR products were denatured at 
951C for 5 min and slowly cooled to room temperature on the 
bench top. Products were automatically loaded on a column 
and eluted with a linear acetonitrile gradient in triethylamine 
acetate buffer (pH 7) at a constant ﬂow rate of 0.5 ml min-1. 
Under these conditions, double-stranded DNA fragments were 
eluted for 5 min. The optimized column temperature against a 
positive control used for each amplicon was varied between 53 
and 58 1C. Eluted DNA fragments were detected by a UV 
detector. All mutations detected by DHPLC were conﬁrmed 
by direct sequencing. However, direct sequencing was applied 
for mutation detection of exons 2–9 and 12–27 on one third 
(60/197) of the cases. The BigDye Terminator Cycle Sequen­
cing kit was employed on ABI PRISM 3130XL Genetic 
Analyzers (Applied Biosystems Inc., Foster City, CA, USA) 
for all sequencing. 
Statistical analyses 
The permutation version of the exact test was done for Hardy– 
Weinberg Equilibrium testing. Fisher’s exact test was em­
ployed for comparing the frequency of genotypes between 
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cases and controls. Two-sided P-values were reported. All 
analyses were done by SAS 9.1.3 software. 
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